The National Institutes of Health Experience with Radiolabeled Monoclonal Antibodies: Lymphoma, Melanoma, and Colon Cancer
Part of the
NATO ASI Series
book series (NSSA, volume 152)
The hybridoma technique of Kohler and Milstein (1975) permits one to develop monoclonal antibodies (MoABS) against tumor-associated antigens that are highly specific, of very strong avidity for the antigen, and available in large quantities as purified protein. In the last few years, MoABS have been developed against tumor associated antigens for most of the common solid tumors: lung, colon, breast, pancreas, prostate, ovary; as well as some that are not so common, such as melanoma and soft-tissue sarcomas. In addition, MoABS that recognize antigens on hematopoietic neoplasms, such as T- and B-cell lymphomas have been developed. In principle, these monoclonal antibodies can be used as carriers for targeting radionuclides to tumors in vivo, as a means of diagnosis and therapy.
KeywordsChronic Lymphocytic Leukemia Blood Pool Tumor Uptake Antigen Content Intraperitoneal Therapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Bunn PA, Carrasquillo JA, Keenan AM, et al.: Radioimmunodetection of cutaneous T-cell lymphoma with In-111-labeled T 101 monoclonal antibody. New Engl. J. Med.
315: 673–680, 1986.PubMedCrossRefGoogle Scholar
Carrasquillo JA, Krohn KA, Beaumier PL, et al.: Diagnosis and Treatment of solid tumors with radiolabeled antibodies and immune fragments. Cancer Treatment Reports
68: 317–318, 1984.PubMedGoogle Scholar
Colcher D, Keenan AM, Larson SM, et al.: Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Can. Res.
44: 5744–5751, 1984.Google Scholar
Estaban JM, Colcher D, Sugarbaker P, et al.: Quantitative and Qualitative Aspects of radiolocalization in colon cancer patients of intravenously administered MoAB B72.3. Int. J. Cancer
30: 50–59, 1987.CrossRefGoogle Scholar
Keenan AM, Colcher D, Larson SM, et al.: Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal B72.3. J. Nucl. Med.
25: 1197–1203, 1984.PubMedGoogle Scholar
Keenan AM, Weinstein JN, Mulshine JL, et al.: Immunolymphoscintigraphy of patients with lymphoma after subcutaneous injection of indium-111 labeled T101 monoclonal antibody. J. Nucl. Med.
28: 42–46, 1987.PubMedGoogle Scholar
Kohler G, Milstein C: Continuous culture of fused cells secreting antibody of predetermined specificity. Nature
256: 495–497, 1975.PubMedCrossRefGoogle Scholar
Larson SM, Carrasquillo JA, Krohn KA, et al.: Localization of I-131 labeled p97 specific Fab fragments in human melanoma as a basis for radiotherapy. J. Can. Inst.
72: 2101–2121, 1983.Google Scholar
Larson SM, Carrasquillo JA, McGuffin RW, et al.: Preliminary clinical experience using an I-131 labeled murine Fab agent, a high molecular weight antigen of human melanoma. Radiology
155: 487–492, 1985.PubMedGoogle Scholar
Larson SM, A tentative biological model for the localization of radiolabeled antibody in tumor: The importance of immunoreactivity. Nucl. Med. Biol. (Int. J. Radiat. Appl. Instrum. Part B
) 13: 393–399, 1986.CrossRefGoogle Scholar
Royston I, Maida JA, Baird SM, et al.: Human T-cell antigens defined by monoclonal antibodies. J. Immunol.
125: 725–731 (1980).PubMedGoogle Scholar
© Springer Science+Business Media New York 1988